Biosyent Inc.
Research Biosyent Inc. (RX) on Bullrun: valuation model: 27.9% undervalued, market cap CAD 159.10M, P/E 17.8, dividend yield 1.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRX
- ExchangeV
- CountryCanada
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCAD
- Valuation signal27.9% undervalued
- Market capCAD 159.10M
- P/E17.8
- Dividend yield1.6%
- Financial periodQ4 2025
- RevenueCAD 9.67M
- Net incomeCAD 1.99M
- Free cash flowCAD 3.47M
- Gross margin77.0%
Valuation Snapshot
Bullrun's latest valuation model marks Biosyent Inc. as 27.9% undervalued; latest market cap is CAD 159.10M; P/E is 17.8; dividend yield is 1.6%.
About Biosyent Inc.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Frequently asked questions
Is Biosyent Inc. overvalued or undervalued?
Bullrun's valuation model currently marks Biosyent Inc. as 27.9% undervalued.
What is Biosyent Inc.'s market cap?
Biosyent Inc.'s market capitalization is CAD 159.10M.
What is Biosyent Inc.'s P/E ratio?
Biosyent Inc.'s price-to-earnings (P/E) ratio is 17.8.
Does Biosyent Inc. pay a dividend?
Biosyent Inc. has a dividend yield of 1.6%.
What does Biosyent Inc. do?
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia;